Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart …
Over the last 12 months, insiders at Tenaya Therapeutics, Inc. have bought $20M and sold $252,746 worth of Tenaya Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tenaya Therapeutics, Inc. have bought $27.92M and sold $123,975 worth of stock each year.
Highest buying activity among insiders over the last 12 months: COLUMN GROUP III GP, LP (10 percent owner) — $20M. GOEDDEL DAVID V () — $20M.
The last purchase of 2,222,222 shares for transaction amount of $10M was made by GOEDDEL DAVID V () on 2024‑02‑12.
2024-11-18 | Sale | SVP, Accounting and Fin. Ops. | 2,258 0.0029% | $2.12 | $4,787 | -2.83% | ||
2024-08-16 | Sale | Chief Executive Officer | 9,748 0.0131% | $2.89 | $28,216 | +1.92% | ||
2024-08-16 | Sale | Chief Medical Officer | 7,428 0.01% | $2.89 | $21,500 | +1.92% | ||
2024-08-16 | Sale | SVP, Accounting and Fin. Ops. | 2,363 0.0032% | $2.89 | $6,840 | 0.00% | ||
2024-03-05 | Sale | Chief Scientific Officer | 3,300 0.0044% | $7.00 | $23,101 | -49.71% | ||
2024-02-20 | Sale | Chief Scientific Officer | 6,569 0.0087% | $5.34 | $35,046 | -31.68% | ||
2024-02-16 | Sale | Chief Scientific Officer | 4,681 0.0064% | $5.86 | $27,431 | -42.88% | ||
2024-02-16 | Sale | Chief Executive Officer | 6,358 0.0087% | $5.86 | $37,258 | -42.88% | ||
2024-02-16 | Sale | Chief Medical Officer | 6,500 0.0088% | $5.86 | $38,090 | -42.88% | ||
2024-02-16 | Sale | Chief Fin. and Bus. Officer | 5,201 0.0071% | $5.86 | $30,478 | -42.88% | ||
2024-02-12 | 2.22M 2.6767% | $4.50 | $10M | -35.51% | ||||
2024-02-12 | 10 percent owner | 2.22M 2.6767% | $4.50 | $10M | -35.51% | |||
2023-08-29 | Sale | Chief Scientific Officer | 7,243 0.0111% | $4.26 | $30,855 | -18.16% | ||
2023-08-16 | Sale | Chief Scientific Officer | 4,007 0.0059% | $3.81 | $15,267 | -4.43% | ||
2023-08-16 | Sale | Chief Executive Officer | 5,563 0.0083% | $3.81 | $21,195 | -4.43% | ||
2023-08-16 | Sale | Chief Medical Officer | 5,563 0.0083% | $3.81 | $21,195 | -4.43% | ||
2023-08-16 | Sale | Chief Fin. and Bus. Officer | 4,452 0.0066% | $3.81 | $16,962 | -4.43% | ||
2023-03-10 | 6,779 0.0092% | $2.60 | $17,596 | +47.13% | ||||
2023-03-10 | 10 percent owner | 6,779 0.0092% | $2.60 | $17,596 | +47.13% | |||
2023-02-08 | 1.5M 1.9331% | $2.60 | $3.9M | +16.12% |
GOEDDEL DAVID V | 13599275 17.1664% | $1.67 | 7 | 0 | +27.92% | |
COLUMN GROUP III GP, LP | 10 percent owner | 13599275 17.1664% | $1.67 | 7 | 0 | +27.92% |
Casdin Eli | director | 6078860 7.6733% | $1.67 | 2 | 0 | <0.0001% |
Casdin Partners Master Fund, L.P. | 10 percent owner | 3224849 4.0707% | $1.67 | 1 | 0 | <0.0001% |
Srivastava Deepak | director | 372435 0.4701% | $1.67 | 1 | 0 | +31.12% |
Column Group Llc | $49.16M | 11.97 | 9.4M | 0% | +$0 | 37.33 | |
Casdin Capital | $35.21M | 8.57 | 6.73M | +5.51% | +$1.84M | 1.74 | |
RA Capital Management, L.P. | $30.1M | 7.33 | 5.76M | +4.5% | +$1.3M | 0.03 | |
BlackRock | $24.59M | 5.99 | 4.7M | +24.14% | +$4.78M | <0.01 | |
T. Rowe Price | $17.5M | 4.26 | 3.35M | -26.36% | -$6.27M | <0.01 |